How is Viatris (VTRS) doing?

Viatris is a company in the drug manufacturers, specialty & generic industry, based in Canonsburg, PA, worth $20.5B. Here is how its shares and business compare with the rest of the market, and where it shows up on our dashboards.

Updated Oct 9, 2026

P3 score

Middling

Viatris shares are up 77% over the past year, 53 points ahead of the S&P 500. Its type is Exhausted Rally. Among large US stocks and funds it ranks in the 94th percentile on market beat, the 20th on staying power and the 40th on business growth. It appears on 6 of our dashboards.

$17.64+77% in a yearWorth $20.5B

Compare with PRGO · OGN · AMGN · PFE

Financials, earnings and news on Stox ›

Past year

The past year

Price against the S&P 500, each set to $100 a year ago. Score is its weekly rank against the market. Select a tile for that score month by month.

VTRS against the S&P 500, past year

$100 a year ago. Viatris +77%, the S&P 500 +16%.

VTRSS&P 500

What kind of stock is it?

Its type on Stox Atlas, from its four scores: beating or lagging the market, a steady or erratic rank, a growing or slowing business, and whether buyers or sellers lead.

Exhausted Rally

BeatingErraticSlowingSold

Has beaten the market erratically on a soft business, and sellers have taken over.

NovDecJanFebMarAprMayJunJulAugSepNow

Exhausted Rally since Sep; Faith Trade before that.

Also Exhausted Rally (50 in all): BDX · HSIC · ALGN · TKR · PFG · USB

EmbracedToppingAccumulatingRejectedStable rankBellwetherDistribution TopCoiled SpringWallflowerHolding rankFaith TradeRolling OverBottom FishedSleepy StapleUnsteady rankHot HandChurning WinnerTurning UpShow-Me GrowerBouncy rankSpeculative PopExhausted RallyFalling KnifeBroken Year

How is it doing against its group?

Its group is Health care, 86 large US stocks and funds whose prices tend to move together. Tools, biotech and large-cap pharma — defensive growth.

VTRS, past year+77%5 of 86 in the group

Rest of the group+20%equal-weighted

S&P 500+16%past year

Viatris is +77% over the past year, against +20% for the rest of the group and +16% for the S&P 500. It ranks 5th of 86 in Health care.

VTRSRest of the group

Best in the groupRVMD Revolution Medicines+297%ILMN Illumina+184%NTRA Natera+133%

Worst in the groupPODD Insulet−57%BSX Boston Scientific−56%RARE Ultragenyx−50%

Its closest rivalsPRGO Perrigo−30%OGN Organon &+35%AMGN Amgen+41%PFE Pfizer+10%

Health care on Stox ›

How much does it move?

Its typical daily move, against its own past year, the market and other large stocks. Swings describe risk, not direction.

About usual Viatris typically moves 2.7% in a day, about usual for it, and it swings less than 63% of large US stocks.

Typical day2.7%about $0.48 a share

Its usual2.8%about usual, 1.0× its year’s average

Against the S&P 5002.5×the index’s typical day is 1.1%

Unusual day±5.4%twice its typical day

Deepest fall, past year−20%now 3% below its high

In the S&P’s down weeks49%of the index’s fall, three years; beta 0.8

Typical daily move (ATR)Its year’s average 2.78%

VTRS on our dashboards

Every question where Viatris appears, in the order of the home page, with its reading and place in that table. Select a question to open it with VTRS highlighted. Select a column to sort.

Question	Reading	Place	Details
Which companies are most exposed to China? The economy and rates	71Notable	11 of 35	Share of sales 16.3% · China sales $2.3B · 3-year change +2.7 pts
How much do stocks move on earnings? Earnings	88Big mover	48 of 60	Reports 2026-11-05 · Typical move 8.7% · Largest 18%
Where are analysts raising estimates? Earnings	89Raised	53 of 60	Change, 1M +0.7% · Change, 3M +2.0% · Next-year EPS $2.52
Who is beating its rivals? Leading stocks	91Ahead	45 of 60	3M +3 pts · 1Y +55 pts · Rivals PRGO, OGN, AMGN, PFE
Whose profit margins are widening? Business quality	98Widening	10 of 60	Change, 1Y +17.8 pts · Operating margin -1% · Gross margin 35%
Which companies could struggle with their debt? Value	97Losing money	12 of 60	Interest cover -0.2x · Net debt / EBITDA 4.5x · Interest a year $480.0M

Go deeper on Stox

VTRS’s full profile: financial statements, earnings and analysts’ estimates, valuation against its sector, recent news with a summary, and its scores in detail.

Open VTRS on Stox ›All 16 types on Atlas ›Its group on Stox ›

How to read this page

How it’s measured. Scores from Stox rank the stock against about 1,200 S&P 500, Nasdaq-100 and Russell 1000 stocks and popular funds, where 100 is best; market beat and staying power use prices, business growth uses revenue, margins and cash flow. Readings on other dashboards come from this site’s pages.

Sources. Daily prices and company financial statements from Financial Modeling Prep; scores and co-movement groups from Stox.

Scores are percentiles: 80 means the stock ranks above 80% of the others on that measure. They describe the recent past and are not advice or a forecast.

Its type follows Stox Atlas: each of the four scores is split at 50. “Steady” means its rank has held, high or low, so it says nothing on its own about direction.

Its group is the cluster of large US stocks whose prices have moved together over five years, with the market’s own moves taken out. The typical daily move is the average true range over 14 days, a measure of how far the price travels in a day including overnight gaps.

For financial statements, earnings and news, see VTRS’s full profile on Stox.

This page is information, not investment advice. About our data and methods ›

Full profile on Stox ›Health care stocks ›PRGO · Perrigo ›OGN · Organon & ›AMGN · Amgen ›PFE · Pfizer ›